Continuing to expand outside the company’s home base of Canada, Aphria Inc. (TSX: APHA; NYSE: APHA) will soon cultivate medical grade marijuana in the Argentinian province of Jujuy.
Aphria’s subsidiary company ABP S.A. just announced the signing of a letter of intent to team up with Cannabis Avatãra Sociedad del Estado, a state-run Argentinian company.
Through that pending deal, ABP is gearing up to cultivate marijuana and extract cannabis oil at a new facility in Jujuy. The location is also slated to produce a variety of cannabis-derivative products besides just dried flower.
Argentina legalized cannabis-based CBD oil for medical purposes in 2017, although patients growing cannabis for personal use on their own private property remains illegal under federal law.
Recently-appointed Aphria President Jakob Ripshtein expressed excitement at the prospect of working directly with the federal government in Argentina to produce cannabis products as the market expands and acceptance of marijuana increases across the nation.
The company’s Vice President of Latin American and Caribbean operations Gabriel Meneses added:
This is the second letter of intent Aphria has signed so far in December to expand its footprint on a global scale.
Earlier this month, the company announced a partnership with Insumos Medicos S.A to supply medical marijuana in Paraguay. That deal will see Insumos Medicos distributing Aphria products through a network of healthcare providers that is already in place.
Aphria has moved forward with a number of Latin and South American operations despite a recent negative short seller report about the company’s LATAM holdings. That report prompted Aphria to appoint an independent group of board members to review all Latin American acquisitions and answer stockholder questions.
The ongoing saga of that developing story was also recently covered in-depth in the fifth episode of Grizzle’s All Time Highs podcast, which can be heard in full over here.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.